Carisbamate

Carisbamate

Clinical data
Trade names	Comfyde (proposed)
ATC code	N03AX19 (WHO)
Identifiers
IUPAC name (S)-2-O-Carbamoyl-1-o-chlorophenyl-ethanol
CAS Number	194085-75-1 Y
PubChem CID	9942577
ChemSpider	8118189 Y
UNII	P7725I9V3Z
ChEMBL	ChEMBL2087003 N
CompTox Dashboard (EPA)	DTXSID70426076
Chemical and physical data
Formula	C9H10ClNO3
Molar mass	215.63 g·mol−1
3D model (JSmol)	Interactive image
SMILES Clc1ccccc1[C@@H](O)COC(=O)N
InChI InChI=1S/C9H10ClNO3/c10-7-4-2-1-3-6(7)8(12)5-14-9(11)13/h1-4,8,12H,5H2,(H2,11,13)/t8-/m0/s1 Y Key:OLBWFRRUHYQABZ-QMMMGPOBSA-N Y
NY (what is this?)  (verify)

Carisbamate (YKP 509, proposed trade name Comfyde) is an experimental anticonvulsant drug that was under development by Johnson & Johnson Pharmaceutical Research and Development but never marketed.